CKDXF

OPTHEA LIMITED

Company Overview

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.

SectorHealthcare

IndustryBiotechnology

Market Cap$14.6M

Last DividendNone

Employees33

CEOJeremy Max Levin Ba Zoology Dphil Mb Bchir

Websitehttps://www.ceryvyn.com

Valuation

Current Price$0.01

Fair Value?$000.00

Valuation?No valuation

Current PE ?N/Aⓘ

Hist. PE ?N/Aⓘ

EPS (TTM) ?-0.13

Forward EPS Growth ?—

Historical Growth ?-14.57%

Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price?

EPS?

Revenue?

Equity?

Pro

Available on the Pro plan

Free Cash Flow?

Pro

Available on the Pro plan

Long Term Debt?

Pro

Available on the Pro plan

Net Profit?

Pro

Available on the Pro plan

Shares Outstanding?

Pro

Available on the Pro plan

Last updated: 10/23/2026, 11:29:54 PM